COMPASS PathwaysCMPS
Recorded

COMPASS Pathways 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration48 minParticipants19

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Good day, ladies and gentlemen, and welcome to the COMPASS Pathways Q3 2026 conference call. At this time, all participants are in a listen-only mode. As a reminder, this call is being recorded. I would now like to introduce your host for today's call, Stephen Schultz.

Steve SchultzSVP of Investor Relations

You may begin. Welcome all of you, and thank you for joining us today for this conference call.

Steve SchultzSVP of Investor Relations

Again, my name is Steve Schultz, Senior Vice President of Investor Relations at COMPASS Pathways. Today, I am joined by Kabir Nath, our Chief Executive Officer, and Lori Englebert, our Chief Commercial Officer. Dr. Steve Levine, our Chief Patient Officer, and Teri Loxam, our Chief Financial Officer, will also be available for the Q&A. The call is being recorded and will be available on the COMPASS Pathways Investor Relations website shortly after the conclusion of the call, and will be available for a period of 30 days. Before we begin, let me remind everyone that during the call today, we will be making statements about our future plans and prospects that constitute forward-looking statements.

Steve SchultzSVP of Investor Relations

Each forward-looking statement is subject to risks and uncertainties that could cause actual results and events to differ materially from those projected in that statement, including those risks and uncertainties described under the heading "Risk Factors" in our most recent filings with the U.S. Securities and Exchange Commission. These forward-looking statements represent our views only as of today, and we specifically disclaim any obligation to update or revise any forward-looking statement, even if our estimates or assumptions change. I will now hand the call to Kabir Nath.

Kabir NathCEO

Thank you, Steve, and thank you all for joining us today. COMPASS continues to make excellent progress toward the potential FDA approval of our psychedelic treatment, which will fundamentally change how mental health is managed. Today, for the estimated 4 million individuals in the U.S. who are impacted by treatment-resistant depression, there is only one approved and marketed drug with that indication, and fewer than 3% of those patients are actually being treated with it. COMP360's profile is unique and compellingly differentiated in delivering both a rapid onset, with effects seen within 24 hours, and durability potentially out to 12 months with just a few treatments. The data also show a safety profile that is generally well tolerated.

Kabir NathCEO

We're confident that COMP360's efficacy in this difficult-to-treat patient population, along with a much less frequent administration schedule, will be highly attractive to patients and prescribers, a confidence that's been well supported by the recent market research that we've been conducting. We will complete our rolling NDA submission in the next two weeks. We have ensured that the filing is the highest quality, with two highly statistically significant phase III studies, together with a positive phase IIb study that together enrolled over 1,000 patients. This will enable the agency to review it with its usual scientific rigor. Given that this has been a rolling submission, and because we've been granted a National Priority Voucher, the ongoing interactions with the FDA remain productive, with a high level of constructive engagement between our respective teams.

Kabir NathCEO

The voucher sets a 1-to-2-month review target for the FDA, so there's the potential for a very rapid approval. Our commercial preparations are moving forward with tremendous momentum. Lori has assembled an all-star team that has the expertise and experience to introduce COMP360 and deliver a successful launch following the potential approval of the TRD indication. Our late-stage trial for post-traumatic stress disorder, or PTSD, which is designed to be registrational, is actively enrolling. PTSD represents an important label expansion opportunity for COMP360. Over 13 million adults in the U.S. are affected by PTSD, and the only approved medicines are two drugs that were approved over 25 years ago, which offer limited effectiveness. Given our robust and strong patent portfolio for COMP360, we're also exploring several other opportunities to expand the label.

Kabir NathCEO

With our demonstrated success in clinical development for this class of medicines and the ability to leverage the commercial infrastructure we're building, we envisage multiple potential future indications. This could drive tremendous long-term revenue and earnings growth for the company, well beyond TRD and PTSD. For now, our priority remains completely focused on maximizing the 2027 launch of COMP360 in TRD. We expect our strong balance sheet, with $444 million of cash on hand as of September 30th, to carry us well through the launch and into 2028. Let me now hand the call to Lori to provide more detail on our commercial strategy and set the stage for some of the key parameters we will be using to evaluate the launch as it progresses through the course of 2027.

Lori EnglebertChief Commercial Officer

Lori? Thanks, Kabir. We continue to rapidly advance commercial launch preparations, and we will be ready for the earliest possible approval date.

Lori EnglebertChief Commercial Officer

As Kabir noted, the NDA submission is well on track to be completed in the next two weeks, and we are encouraged by the ongoing and productive FDA interactions. We remain optimistic for approval in a timeframe that reflects the spirit of the National Priority Voucher. The emerging product profile of COMP360 offers both rapid onset of action, seen within 24 hours, and remarkable durability not previously available in depression treatments. Combined with a generally well-tolerated and safe profile, COMP360 is highly differentiated, and we are confident that clinicians will adopt COMP360 as the treatment of choice for patients with TRD.

Lori EnglebertChief Commercial Officer

COMPASS is well-positioned to establish this emerging field of psychedelic medicine, not only by bringing an innovative and important new product to market with COMP360, but also the manner in which we do it. As the leader, we have a responsibility to patients and providers to set the gold standard for commercial execution. The commercial leadership team is one of the most highly experienced that I have ever worked with. Collectively, we have led over 65 product launches at companies like J&J, Gilead, Otsuka, Axsome, and Intra-Cellular. The level of passion and expertise that this team brings is remarkable. Over the past several quarters, the commercial leaders have been building each of their respective functional teams, and the level of talent that we have been able to attract speaks volumes about the opportunity these individuals see at COMPASS.

Lori EnglebertChief Commercial Officer

At this time, all planned non-field-based commercial roles are filled, and we are now shifting focus to hiring a world-class field force. The recruiting for the field-based roles is going remarkably well, with an incredibly high level of interest. In addition, over the past quarter, our newly expanded team of medical science liaisons have continued to educate clinicians on TRD and COMP360, and our payer access team has been actively engaging with payers across regional and national accounts, as well as state-level plans. The marketing and launch strategy work remains on track, and we are confident that we will be launch-ready at the earliest possible time point. One key initiative of our commercial preparations has been extensive market research to fully understand the human impact of TRD. COMPASS has completed multiple research projects that have involved patients, caregivers, prescribers, and providers.

Lori EnglebertChief Commercial Officer

One of the most impactful and consistent findings from this research is the significant burden of TRD. For example, when asked about their day-to-day experience, nearly all, 95%, of surveyed patients describe themselves as constantly struggling and barely able to get by on a day-to-day basis. For the many people with TRD, the path to relief can mean years of trial and error through the many treatments approved for MDD, which have not demonstrated efficacy in TRD, and the continual therapy switching is a burden of its own. After having tried multiple treatments without meaningful symptom improvement, approximately 75% of TRD patients felt emotionally exhausted from the false hope of trying treatments that ultimately offered little relief, and more than two-thirds of patients state that living with TRD has made them feel hopeless about their future.

Lori EnglebertChief Commercial Officer

The impact of TRD extends beyond depressive symptoms, robbing patients of special moments and opportunities, as well as profoundly affecting the families and caregivers who support them. Surveyed patients reported missing family events, reduced work hours, and even resigning from jobs because of their depression. More than half of surveyed caregivers feel emotionally exhausted by the cyclic nature of searching for effective treatments for their loved ones, and approximately 70% say TRD affects the whole family's social, physical, and/or mental health. These insights provide an important perspective on the real-world impact of TRD and underscore the urgent need for new TRD treatments like COMP360. This unmet need highlights the significant market opportunity for COMPASS, potentially reaching the estimated 4 million patients in the U.S.

Lori EnglebertChief Commercial Officer

Today, less than 3% of these patients are accessing the only marketed and approved TRD treatment, SPRAVATO, due largely to the burden associated with the required frequency of dosing. One of the biggest advantages of COMP360 is its durability with infrequent dosing. This is why we are confident in its potential. At launch, we will leverage the well-established interventional psychiatry treatment center infrastructure. These treatment sites are specifically designed to support in-office treatments for products that require multi-hour support and monitoring. This established infrastructure has existing capacity and, importantly, is already equipped with the staff and operational know-how needed to support additional multi-hour treatments like COMP360. Seven years ago, when SPRAVATO launched, this infrastructure did not exist. Today, there are more than 8,500 interventional psychiatry treatment centers in place across the U.S., and it continues to grow rapidly.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day